Similar articles

Abstract: coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first affected humans in China on December 31, 2019 (Shi et al., 2020). Coronaviruses generally cause mild, self-limiting upper respiratory tract infections in humans, such as the common cold, pneumonia, and gastroenteritis (To et al., 2013; Berry et al., 2015; Chan et al., 2015). According to the Report of the World Health Organization (WHO)-China Joint Mission on COVID-19 (WHO, 2020), the case fatality rate of COVID-19 increases with age, while the rate among males is higher than that among females (4.7% and 2.8%, respectively). Since an effective vaccine and specific anti-viral drugs are still under development, passive immunization using the convalescent plasma (CP) of recovered COVID-19 donors may offer a suitable therapeutic strategy for severely ill patients in the meantime. So far, several studies have shown therapeutic efficacy of CP transfusion in treating COVID-19 cases. A pilot study first reported that transfusion of CP with neutralizing antibody titers above 1:640 was well tolerated and could potentially improve clinical outcomes through neutralizing viremia in severe COVID-19 cases (Chen et al., 2020). Immunoglobulin G (IgG) and IgM are the most abundant and important antibodies in protecting the human body from viral attack (Arabi et al., 2015; Marano et al., 2016). Our study aimed to understand the aspects of plasma antibody titer levels in convalescent patients, as well as assessing the clinical characteristics of normal, severely ill, and critically ill patients, and thus provide a basis for guiding CP therapy. We also hoped to find indicators which could serve as a reference in predicting the progression of the disease.

浙江省新冠病毒肺炎患者的临床特征和血浆抗体滴度的调查与分析

[1]Arabi Y, Balkhy H, Hajeer AH, et al., 2015. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. SpringerPlus, 4:709.

[2]Berry M, Gamieldien J, Fielding BC, 2015. Identification of new respiratory viruses in the new millennium. Viruses, 7(3):996-1019.

[3]Chan JFW, Yao YF, Yeung ML, et al., 2015. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis, 212(12):1904-1913.

[4]Chen L, Xiong J, Bao L, et al., 2020. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis, 20(4):398-400.

[5]Huang DQ, Chen R, Wang YQ, et al., 2019. Development of a colloidal gold-based immunochromatographic strip for rapid detection of Rice stripe virus. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 20(4):343-354.

[6]Lee YL, Liao CH, Liu PY, et al., 2020. Dynamics of anti-SARS-CoV-2 IgM and IgG antibodies among COVID-19 patients. J Infect, 81(2):E55-E58.

[7]Li L, Tong XL, Chen HW, et al., 2020. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation. Transfusion, 60(8):1765-1772.

[8]Liu YL, Sun WW, Li J, et al., 2020. Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. medRxiv, preprint.

[9]Long QX, Liu BZ, Deng HJ, et al., 2020. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med, 26(6):845-848.

[10]Marano G, Vaglio S, Pupella S, et al., 2016. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus, 14(2):152-157.

[11]Samanta D, Willis E, 2016. Focal seizure associated with human parvovirus B19 infection in a non-encephalopathic child. World J Pediatr, 12(1):118-120.

[12]Shi Y, Wang G, Cai XP, et al., 2020. An overview of COVID-19. J Zhejiang Univ Sci B (Biomed & Biotechnol), 21(5):343-360.

[13]Singh L, Mishra S, Prasanna S, et al., 2015. Seroprevalence of TORCH infections in antenatal and HIV positive patient populations. Med J Armed Forces India, 71(2):135-138.

[14]To KKW, Hung IFN, Chan JFW, et al., 2013. From SARS coronavirus to novel animal and human coronaviruses. J Thorac Dis, 5(S2):S103-S108.

[15]WHO, 2020. Report of the WHO-China Joint Mission on coronavirus disease 2019 (COVID-19). https://www.who. int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)

[16]Zhang LB, Pang RR, Xue X, et al., 2020. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Aging, 12(8):6536-6542.

[17]https://doi.org/10.18632/aging.103102

[18]List of electronic supplementary materials

[19]Fig. S1 Correlation between IgG/IgM titer and different laboratory indexes